Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival

Cell Cycle

Volumn 12, Issue 18, 2013, Pages 2937-2947

  Braun, Frédérique ^a   De Carné Trécesson, Sophie ^a   Bertin Ciftci, Joséphine ^a,c   Juin, Philippe ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Bcl 2 family; Cas pase; E2F 1; Myc; NF B

Indexed keywords

CASPASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PERMEABILIZATION; CELL SURVIVAL; ENZYME ACTIVATION; HUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION;

BCL-2 FAMILY; CASPASE; E2F-1; MYC; NF-ΚB;

APOPTOSIS; CASPASES; CELL MEMBRANE PERMEABILITY; E2F1 TRANSCRIPTION FACTOR; HUMANS; MITOCHONDRIA; NEOPLASMS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84884864240     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25972     Document Type: Article

References (88)

1. Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11:621-32; PMID:20683470; http://dx.doi.org/10.1038/nrm2952
2. Juin P, Geneste O, Gautier F, Depil S, Campone M. Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer 2013; 13:455-65; PMID:23783119; http://dx.doi.org/10.1038/nrc3538
3. Vo T-T, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 2012; 151:344-55; PMID:23063124; http://dx.doi.org/10.1016/j.cell.2012.08.038
4. Ni Chonghaile T, Sarosiek KA, Vo T-T, Ryan JA, Tammareddi A, Moore VdelG, Deng J, Anderson KC, Richardson P, Tai YT, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011; 334:1129-33; PMID:22033517; http://dx.doi.org/10.1126/science.1206727
5. Tait SWG, Parsons MJ, Llambi F, Bouchier-Hayes L, Connell S, Muñoz-Pinedo C, Green DR. Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev Cell 2010; 18:802-13; PMID:20493813; http://dx.doi.org/10.1016/j.devcel.2010.03.014
6. Khalil H, Peltzer N, Walicki J, Yang JY, Dubuis G, Gardiol N, Held W, Bigliardi P, Marsland B, Liaudet L, et al. Caspase-3 protects stressed organs against cell death. Mol Cell Biol 2012; 32:4523-33; PMID:22949508; http://dx.doi.org/10.1128/MCB.00774-12
7. Song JH, Kandasamy K, Zemskova M, Lin Y-W, Kraft AS. The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res 2011; 71:506-15; PMID:21084274; http://dx.doi.org/10.1158/0008-5472.CAN-10-1977
8. Bertin-Ciftci J, Barré B, Le Pen J, Maillet L, Couriaud C, Juin P, Braun F. pRb/E2F-1-mediated caspasedependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737. Cell Death Differ 2013; 20:755-64; PMID:23429261; http://dx.doi.org/10.1038/cdd.2013.6
9. Bonneau B, Prudent J, Popgeorgiev N, Gillet G. Non-apoptotic roles of Bcl-2 family: the calcium connection. Biochim Biophys Acta 2013; 1833:1755-65; PMID:23360981; http://dx.doi.org/10.1016/j.bbamcr.2013.01.021
10. Li C, Fox CJ, Master SR, Bindokas VP, Chodosh LA, Thompson CB. Bcl-X(L) affects Ca(2+) homeostasis by altering expression of inositol 1,4,5-trisphosphate receptors. Proc Natl Acad Sci U S A 2002; 99:9830-5; PMID:12118121; http://dx.doi.org/10.1073/pnas.152571899
11. Monaco G, Vervliet T, Akl H, Bultynck G. The selective BH4-domain biology of Bcl-2-family members: IP3Rs and beyond. Cell Mol Life Sci 2013; 70:1171-83; PMID:22955373; http://dx.doi.org/10.1007/s00018-012-1118-y
12. Zhu L, Yu Y, Chua BH, Ho YS, Kuo TH. Regulation of sodium-calcium exchange and mitochondrial energetics by Bcl-2 in the heart of transgenic mice. J Mol Cell Cardiol 2001; 33:2135-44; PMID:11735260; http://dx.doi.org/10.1006/ jmcc.2001.1476
13. Xu C, Xu W, Palmer AE, Reed JC. BI-1 regulates endoplasmic reticulum Ca2+ homeostasis downstream of Bcl-2 family proteins. J Biol Chem 2008; 283:11477-84; PMID:18299329; http://dx.doi.org/10.1074/jbc.M708385200
14. Cárdenas C, Miller RA, Smith I, Bui T, Molgó J, Müller M, Vais H, Cheung KH, Yang J, Parker I, et al. Essential regulation of cell bioenergetics by constitutive InsP3 receptor Ca2+ transfer to mitochondria. Cell 2010; 142:270-83; PMID:20655468; http://dx.doi.org/10.1016/j.cell.2010.06.007
15. Danial NN, Gramm CF, Scorrano L, Zhang CY, Krauss S, Ranger AM, Datta SR, Greenberg ME, Licklider LJ, Lowell BB, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature 2003; 424:952-6; PMID:12931191; http://dx.doi.org/10.1038/nature01825
16. Chen Y-B, Aon MA, Hsu Y-T, Soane L, Teng X, McCaffery JM, Cheng WC, Qi B, Li H, Alavian KN, et al. Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential. J Cell Biol 2011; 195:263-76; PMID:21987637; http://dx.doi.org/10.1083/jcb.201108059
17. Alavian KN, Li H, Collis L, Bonanni L, Zeng L, Sacchetti S, Lazrove E, Nabili P, Flaherty B, Graham M, et al. Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase. Nat Cell Biol 2011; 13:1224-33; PMID:21926988; http://dx.doi.org/10.1038/ncb2330
18. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 2012; 14:575-83; PMID:22544066; http://dx.doi.org/10. 1038/ncb2488
19. Yi CH, Pan H, Seebacher J, Jang IH, Hyberts SG, Heffron GJ, Vander Heiden MG, Yang R, Li F, Locasale JW, et al. Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell 2011; 146:607-20; PMID:21854985; http://dx.doi.org/10.1016/j.cell.2011.06.050
20. Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K, Tavernarakis N, et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J 2007; 26:2527-39; PMID:17446862; http://dx.doi.org/10.1038/sj.emboj.7601689
21. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhas O, Shokat KM, Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010; 17:249-61; PMID:20227039; http://dx.doi.org/10.1016/j.ccr.2010.01.021
22. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004; 1644:83-94; PMID:14996493; http://dx.doi.org/10.1016/j.bbamcr.2003.08.012
23. Rizzuto R, Marchi S, Bonora M, Aguiari P, Bononi A, De Stefani D, Giorgi C, Leo S, Rimessi A, Siviero R, et al. Ca(2+) transfer from the ER to mitochondria: when, how and why. Biochim Biophys Acta 2009; 1787:1342-51; PMID:19341702; http://dx.doi.org/10.1016/j.bbabio.2009.03.015
24. Choi B-H, Yoon HS. FKBP38-Bcl-2 interaction: a novel link to chemoresistance. Curr Opin Pharmacol 2011; 11:354-9; PMID:21571591; http://dx.doi.org/10.1016/j.coph.2011.04.013
25. Shirane M, Nakayama KI. Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol 2003; 5:28-37; PMID:12510191; http://dx.doi.org/10.1038/ncb894
26. Massaad CA, Portier BP, Taglialatela G. Inhibition of transcription factor activity by nuclear compartmentassociated Bcl-2. J Biol Chem 2004; 279:54470-8; PMID:15471874; http://dx.doi.org/10.1074/jbc. M407659200
27. Portier BP, Taglialatela G. Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression. J Biol Chem 2006; 281:40493-502; PMID:17090549; http://dx.doi.org/10.1074/jbc.M606181200
28. Beverly LJ. Regulation of anti-apoptotic BCL2- proteins by non-canonical interactions: the next step forward or two steps back? J Cell Biochem 2012; 113:3-12; PMID:21898539; http://dx.doi.org/10.1002/jcb.23335
29. Monaco G, Decrock E, Akl H, Ponsaerts R, Vervliet T, Luyten T, De Maeyer M, Missiaen L, Distelhorst CW, De Smedt H, et al. Selective regulation of IP3- receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl. Cell Death Differ 2012; 19:295-309; PMID:21818117; http://dx.doi.org/ 10.1038/cdd.2011.97
30. Laulier C, Lopez BS. The secret life of Bcl-2: apoptosis- independent inhibition of DNA repair by Bcl-2 family members. Mutat Res 2012; 751:247-57; PMID:22677530; http://dx.doi.org/10.1016/j.mrrev.2012.05.002
31. Fujise K, Zhang D, Liu J, Yeh ET. Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J Biol Chem 2000; 275:39458-65; PMID:10978339; http://dx.doi.org/10.1074/jbc. M006626200
32. Barillé-Nion S, Bah N, Véquaud E, Juin P. Regulation of cancer cell survival by BCL2 family members upon prolonged mitotic arrest: opportunities for anticancer therapy. Anticancer Res 2012; 32:4225-33; PMID:23060542
33. Bruey J-M, Bruey-Sedano N, Luciano F, Zhai D, Balpai R, Xu C, Kress CL, Bailly-Maitre B, Li X, Osterman A, et al. Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1. Cell 2007; 129:45-56; PMID:17418785; http://dx.doi.org/10.1016/j.cell.2007.01.045
34. Faustin B, Chen Y, Zhai D, Le Negrate G, Lartigue L, Satterthwait A, Reed JC. Mechanism of Bcl-2 and Bcl-X(L) inhibition of NLRP1 inflammasome: loop domain-dependent suppression of ATP binding and oligomerization. Proc Natl Acad Sci U S A 2009; 106:3935-40; PMID:19223583; http://dx.doi.org/10.1073/pnas. 0809414106
35. Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009; 137:413-31; PMID:19410540; http://dx.doi.org/10.1016/j.cell. 2009.04.037
36. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458:1127-30; PMID:19407794; http://dx.doi.org/10.1038/nature07986
37. Froesch BA, Aimé-Sempé C, Leber B, Andrews D, Reed JC. Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain. J Biol Chem 1999; 274:6469-75; PMID:10037739; http://dx.doi.org/10.1074/jbc.274.10.6469
38. Montero J, Dutta C, van Bodegom D, Weinstock D, Letai A. p53 regulates a non-apoptotic death induced by ROS. Cell Death Differ 2013; PMID:23703322; http://dx.doi.org/10.1038/cdd.2013.52
39. Polager S, Ginsberg D. E2F - at the crossroads of life and death. Trends Cell Biol 2008; 18:528-35; PMID:18805009; http://dx.doi.org/10.1016/j.tcb.2008. 08.003
40. Stevens C, La Thangue NB. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst) 2004; 3:1071-9; PMID:15279795; http://dx.doi.org/10.1016/j.dnarep.2004.03.034
41. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, Pützer BM. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73- miR-205 circuitry. Cell Cycle 2012; 11:3067-78; PMID:22871739; http://dx.doi.org/10.4161/cc.21476
42. Ianari A, Natale T, Calo E, Ferretti E, Alesse E, Screpanti I, Haigis K, Gulino A, Lees JA. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 2009; 15:184-94; PMID:19249677; http://dx.doi.org/10.1016/ j.ccr.2009.01.026
43. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006; 13:1351-9; PMID:16763616; http://dx.doi.org/10. 1038/sj.cdd.4401987
44. Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med 1996; 183:2219-26; PMID:8642331; http://dx.doi.org/10.1084/jem.183.5.2219
45. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996; 15:6979-90; PMID:9003774
46. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 1996; 271:12695-8; PMID:8663032
47. Linette GP, Li Y, Roth K, Korsmeyer SJ. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci U S A 1996; 93:9545-52; PMID:8790367; http://dx.doi.org/10.1073/pnas. 93.18.9545
48. Quinn LM, Richardson H. Bcl-2 in cell cycle regulation. Cell Cycle 2004; 3:7-9; PMID:14657653; http://dx.doi.org/10.4161/cc.3.1.602
49. Lind EF, Wayne J, Wang QZ, Staeva T, Stolzer A, Petrie HT. Bcl-2-induced changes in E2F regulatory complexes reveal the potential for integrated cell cycle and cell death functions. J Immunol 1999; 162:5374-9; PMID:10228014
50. Vairo G, Soos TJ, Upton TM, Zalvide J, DeCaprio JA, Ewen ME, Koff A, Adams JM. Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation. Mol Cell Biol 2000; 20:4745-53; PMID:10848600; http://dx.doi.org/10.1128/MCB.20.13.4745-4753.2000
51. Greider C, Chattopadhyay A, Parkhurst C, Yang E. BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases. Oncogene 2002; 21:7765-75; PMID:12420213; http://dx.doi.org/10.1038/sj.onc.1205928
52. Janumyan Y, Cui Q, Yan L, Sansam CG, Valentin M, Yang E. G0 function of BCL2 and BCL-xL requires BAX, BAK, and p27 phosphorylation by Mirk, revealing a novel role of BAX and BAK in quiescence regulation. J Biol Chem 2008; 283:34108-20; PMID:18818203; http://dx.doi.org/10.1074/jbc. M806294200
53. Youn CK, Cho HJ, Kim SH, Kim HB, Kim MH, Chang IY, Lee JS, Chung MH, Hahm KS, You HJ. Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity. Nat Cell Biol 2005; 7:137-47; PMID:15619620; http://dx.doi.org/10.1038/ncb1215
54. Wang J, Beauchemin M, Bertrand R. Phospho-Bclx( L)(Ser62) plays a key role at DNA damage-induced G(2) checkpoint. Cell Cycle 2012; 11:2159-69; PMID:22617334; http://dx.doi.org/10.4161/cc.20672
55. Mac Fhearraigh S, Mc Gee MM. Cyclin B1 interacts with the BH3-only protein Bim and mediates its phosphorylation by Cdk1 during mitosis. Cell Cycle 2011; 10:3886-96; PMID:22071694; http://dx.doi.org/10.4161/cc.10.22.18020
56. Janumyan YM, Sansam CG, Chattopadhyay A, Cheng N, Soucie EL, Penn LZ, Andrews D, Knudson CM, Yang E. Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J 2003; 22:5459-70; PMID:14532118; http://dx.doi.org/10.1093/emboj/cdg533
57. Fattman CL, Delach SM, Dou QP, Johnson DE. Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposideinduced apoptosis. Oncogene 2001; 20:2918-26; PMID:11420704; http://dx.doi.org/10.1038/sj.onc. 1204414
58. Vallabhapurapu S, Karin M. Regulation and function of NFkappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27:693-733; http://dx.doi.org/10.1146/annurev.immunol. 021908.132641; PMID:19302050
59. Luo J-L, Kamata H, Karin M. The anti-death machinery in IKK/NFkappaB signaling. J Clin Immunol 2005; 25:541-50; PMID:16380818; http://dx.doi.org/10. 1007/s10875-005-8217-6
60. Kanarek N, London N, Schueler-Furman O, Ben- Neriah Y. Ubiquitination and degradation of the inhibitors of NFkappaB. Cold Spring Harb Perspect Biol 2010; 2:a000166; PMID:20182612; http://dx.doi.org/10.1101/cshperspect.a000166
61. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NFkappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A 1999; 96:9136-41; PMID:10430908; http://dx.doi.org/10.1073/pnas.96.16.9136
62. Ravi R, Bedi A, Fuchs EJ, Bedi A. CD95 (Fas)- induced caspase-mediated proteolysis of NFkappaB. Cancer Res 1998; 58:882-6; PMID:9500443
63. Levkau B, Scatena M, Giachelli CM, Ross R, Raines EW. Apoptosis overrides survival signals through a caspase-mediated dominant-negative NFkappa B loop. Nat Cell Biol 1999; 1:227-33; PMID:10559921; http://dx.doi.org/10.1038/12050
64. Tang G, Yang J, Minemoto Y, Lin A. Blocking caspase-3-mediated proteolysis of IKKbeta suppresses TNFalpha-induced apoptosis. Mol Cell 2001; 8:1005-16; PMID:11741536; http://dx.doi.org/10.1016/S1097-2765(01)00380-X
65. Pahl HL. Activators and target genes of Rel/NFkappaB transcription factors. Oncogene 1999; 18:6853-66; PMID:10602461; http://dx.doi.org/10.1038/sj. onc.1203239
66. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431-6; PMID:16724054; http://dx.doi.org/10.1038/nature04870
67. Giorgini S, Trisciuoglio D, Gabellini C, Desideri M, Castellini L, Colarossi C, Zangemeister-Wittke U, Zupi G, Del Bufalo D. Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Mol Cancer Res 2007; 5:761-71; PMID:17699103; http://dx.doi.org/10.1158/1541-7786.MCR-07-0088
68. Gabellini C, Castellini L, Trisciuoglio D, Kracht M, Zupi G, Del Bufalo D. Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma. J Neurochem 2008; 107:871-82; PMID:18786178; http://dx.doi.org/10.1111/j.1471-4159.2008.05661.x
69. Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M. bcl-2 over-expression enhances NFkappaB activity and induces mmp-9 transcription in human MCF7(ADR) breastcancer cells. Int J Cancer 2000; 86:188-96; PMID:10738245; http://dx.doi.org/10.1002/(SICI)1097-0215(20000415)86:23.0.CO;2-W
70. Karl E, Zhang Z, Dong Z, Neiva KG, Soengas MS, Koch AE, Polverini PJ, Núñez G, Nör JE. Unidirectional crosstalk between Bcl-xL and Bcl-2 enhances the angiogenic phenotype of endothelial cells. Cell Death Differ 2007; 14:1657-66; PMID:17572663; http://dx.doi.org/10.1038/sj.cdd.4402174
71. Kang J, Pervaiz S. Crosstalk between Bcl-2 family and Ras family small GTPases: potential cell fate regulation? Front Oncol 2012; 2:206; PMID:23316476
72. Regula KM, Ens K, Kirshenbaum LA. IKK beta is required for Bcl-2-mediated NFkappa B activation in ventricular myocytes. J Biol Chem 2002; 277:38676-82; PMID:12167626; http://dx.doi.org/10.1074/jbc. M206175200
73. de Moissac D, Zheng H, Kirshenbaum LA. Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappaB signaling pathway for suppression of apoptosis. J Biol Chem 1999; 274:29505-9; PMID:10506215; http://dx.doi.org/10.1074/jbc.274. 41.29505
74. Kucharczak J, Simmons MJ, Fan Y, Gélinas C. To be, or not to be: NFkappaB is the answer - role of Rel/NFkappaB in the regulation of apoptosis. Oncogene 2003; 22:8961-82; PMID:14663476; http://dx.doi.org/10.1038/sj.onc. 1207230
75. Hour TC, Chen L, Lin JK. Suppression of transcription factor NFkappaB activity by Bcl-2 protein in NIH3T3 cells: implication of a novel NFkappaB p50- Bcl-2 complex for the anti-apoptotic function of Bcl-2. Eur J Cell Biol 2000; 79:121-9; PMID:10727020; http://dx.doi.org/10.1078/S0171-9335(04)70014-X
76. Song JH, Kandasamy K, Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 2008; 283:25003-13; PMID:18599488; http://dx.doi.org/10.1074/jbc.M802511200
77. Hardy K, Mansfield L, Mackay A, Benvenuti S, Ismail S, Arora P, O'Hare MJ, Jat PS. Transcriptional networks and cellular senescence in human mammary fibroblasts. Mol Biol Cell 2005; 16:943-53; PMID:15574883; http://dx.doi.org/10. 1091/mbc. E04-05-0392
78. Acosta JC, O'Loghlen A, Banito A, Raguz S, Gil J. Control of senescence by CXCR2 and its ligands. Cell Cycle 2008; 7:2956-9; PMID:18838863; http://dx.doi.org/10.4161/cc.7.19.6780
79. Gorgoulis VG, Halazonetis TD. Oncogeneinduced senescence: the bright and dark side of the response. Curr Opin Cell Biol 2010; 22:816-27; PMID:20807678; http://dx.doi.org/10.1016/j.ceb.2010.07.013
80. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008; 14:447-57; PMID:19061836; http://dx.doi.org/10.1016/j.ccr.2008.10.018
81. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432:307-15; PMID:15549092; http://dx.doi.org/10.1038/nature03098
82. Juin P, Hueber AO, Littlewood T, Evan G. c-Mycinduced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev 1999; 13:1367-81; PMID:10364155; http://dx.doi.org/10.1101/gad.13.11.1367
83. Juin P, Hunt A, Littlewood T, Griffiths B, Swigart LB, Korsmeyer S, Evan G. c-Myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol 2002; 22:6158-69; PMID:12167710; http://dx.doi.org/10.1128/MCB.22.17.6158-6169. 2002
84. Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, et al. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol Cancer 2011; 10:110; PMID:21899728; http://dx.doi.org/10.1186/1476-4598-10-110
85. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene 2008; 27:6462-72; PMID:18955973; http://dx.doi.org/10.1038/onc.2008.312
86. Jin Z, May WS, Gao F, Flagg T, Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J Biol Chem 2006; 281:14446-56; PMID:16554306; http://dx.doi.org/10.1074/jbc. M511914200
87. Lu Q, Hong W. Bcl2 enhances c-Myc-mediated MMP-2 expression of vascular smooth muscle cells. Cell Signal 2009; 21:1054-9; PMID:19258038; http://dx.doi.org/10.1016/j.cellsig.2009.02.020
88. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008